10 Best Penny Stocks to Buy for 2026

Page 9 of 9

1. Geron Corporation (NASDAQ:GERN)

Stock Upside Potential: 191.97%

Share Price: $1.43

Number of Hedge Fund Holders: 37

Geron Corporation (NASDAQ:GERN) is one of the best penny stocks to buy for 2026. On January 6, Geron Corporation (NASDAQ:GERN) amended its loan agreement with Biopharma Credit Investments and BPCR Limited Partnership. The deal relates to a secured term loan facility of up to $250 million.

Under the new agreement, the facility is to be split into three tranches. A $125 million Tranche A loan was funded on November 1, 2024, $75 million Tranche B loan is available to the company, and a $50 million Tranche C loan is available to the company upon achieving the specified trailing 12-month RYTELO revenue milestone. Geron could prepay the loans, in part or in full, before maturity, subject to a premium ranging from 1% to 3% of the principal.

The credit facility amendment comes on the heels of the company’s affirmation of a strategic restructuring plan. On December 11, Geron Corporation (NASDAQ:GERN) announced a restructuring plan to cut about one‑third of its workforce, eliminating roughly 85 positions from its 260‑employee base. The move is intended to streamline operations while focusing on U.S. sales of Rytelo (imetelstat) in LR‑MDS, international expansion, and the Phase 3 IMpactMF trial in myelofibrosis. Despite reporting $183.4 million in revenue over the past year, Rytelo sales have recently stagnated, with Q3 2025 revenues slipping below Q2 and October tracking at $15 million.

H.C. Wainwright reiterated a Neutral rating, noting expenses should decline in 2026 and profitability could be reached by the second half of the year. Geron plans to update its European commercialization strategy in the first half of 2026 and release interim IMpactMF survival data later in the year. The company maintains strong financial flexibility with more cash than debt and a current ratio of 5.96, though analysts do not expect profitability in 2025.

Geron Corporation (NASDAQ:GERN) is a commercial-stage biopharmaceutical company focused on developing and selling therapies for blood cancers. Its lead product, Rytelo (imetelstat), is FDA-approved for certain lower-risk myelodysplastic syndromes.

While we acknowledge the potential of Geron Corporation (NASDAQ:GERN) to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GERN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 11 Best Fertilizer Stocks to Invest In and 10 Best Beaten Down Technology Stocks to Buy According to Hedge Funds.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.

Page 9 of 9